Anti-inflammatory cytokines in endometriosis

Wen-Jie Zhou1,2 · Hui-Li Yang1 · Jun Shao1,3 · Jie Mei4 · Kai-Kai Chang3 · Rui Zhu5 · Ming-Qing Li1,6

Received: 28 October 2018 / Revised: 29 January 2019 / Accepted: 25 February 2019
© Springer Nature Switzerland AG 2019

Abstract
Although the pathogenesis of endometriosis is not fully understood, it is often considered to be an inflammatory disease. An increasing number of studies suggest that differential expression of anti-inflammatory cytokines (e.g., interleukin-4 and -10, and transforming growth factor-β1) occurs in women with endometriosis, including in serum, peritoneal fluid and ectopic lesions. These anti-inflammatory cytokines also have indispensable roles in the progression of endometriosis, including by promoting survival, growth, invasion, differentiation, angiogenesis, and immune escape of the endometriotic lesions. In this review, we provide an overview of the expression, origin, function and regulation of anti-inflammatory cytokines in endometriosis, with brief discussion and perspectives on their future clinical implications in the diagnosis and therapy of the disease.

Keywords
Endometriosis · Cytokine · Anti-inflammatory · IL-10 · TGF-β · Endometrial stromal cells · Macrophage · T cells · NK cells

Introduction

Endometriosis is one of the most common gynecological diseases. It is a chronic disorder that affects 10% of all women of reproductive age, characterized by the presence of endometrial tissue outside the uterine cavity [1]. This disease can cause long-term chronic pelvic pain, dysmenorrhea, severe dyspareunia, infertility and pelvic-organ dysfunction [2]. Despite improvements in the diagnosis and understanding of endometriosis, many patients with endometriosis suffer due to ineffective non-invasive diagnostic methods and treatments, which are often associated with multiple side effects and high-recurrence rates [3, 4]. Therefore, endometriosis profoundly impairs the quality of life of the patients with a negative impact on social and family life, and high-healthcare costs [5, 6].

Although the pathophysiology of endometriosis is not fully understood, accumulating evidence indicates that combinations of hormonal, immunologic, genetic and environmental factors are involved in the origin and development of endometriosis [1]. Evidence suggests that aberrant immunologic and inflammatory responses, in particular, increased levels of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and IL-17A, are present in the serum, peritoneal fluid (PF) and ectopic lesions of patients with endometriosis [7–16]. Due to the

Wen-Jie Zhou and Hui-Li Yang co-first author.

© Springer
crucial role of inflammatory immune responses in the development and progression of endometriosis, this disease is considered to be an immune-related chronic inflammatory disease [17–19]. Subsequently, these pro-inflammatory cytokines have been investigated as possible non-invasive serum biomarkers for diagnosis [13, 14, 20–22] or potential targets for treatment of endometriosis [23–29], although certain findings have been contradictory [30–33].

The human immune response is mediated by a highly complex network of regulatory elements. Among these, anti-inflammatory cytokines are a series of immunoregulatory molecules that control the pro-inflammatory cytokine response [34]. Under physiological conditions, anti-inflammatory cytokines limit the potentially damaging effects of sustained or excessive inflammatory reactions. Under pathological conditions, anti-inflammatory mediators may have insufficient control over pro-inflammatory activities in immune-mediated diseases, or overcompensate and inhibit the immune response, increasing the risk of systemic infection.

As early as the 1990s, studies reported that anti-inflammatory cytokines (such as IL-10 and IL-4) were also elevated in the peripheral blood and PF of patients with endometriosis [35–37]; however, this did not receive widespread attention. In the past 10 years, the differential expression of these anti-inflammatory cytokines and their role in the pathogenesis of endometriosis has been gradually revealed. From an immunological viewpoint, studies have indicated that endometriosis is not just an inflammatory disorder, but a disease associated with pro-inflammation and anti-inflammation activity. Therefore, the aim of this review is to discuss the changes, cell and tissue origin, regulatory factors and role of anti-inflammatory cytokines associated with endometriosis, and in particular, the communication between endometrial cells and immune cells in the ectopic lesion microenvironment (Fig. 1).

### Anti-inflammatory cytokines

**T helper (TH) 2 cytokines**

IL-4 and IL-10 family proteins are the main Th2 anti-inflammatory cytokines. Several lines of evidence indicate that the Th2 immune response is associated with endometriosis [38, 39]. As shown in Table 1, accumulating evidence has demonstrated that anti-inflammatory cytokines IL-4 [38–41] and IL-10 [40, 42–46] are sharply increased in peripheral lymphocytes and the ectopic endometrium of women with endometriosis. Notably, a significant increase in IL-4 [44, 47, 48] and IL-10 levels [39, 46, 48–55] in PF from women with endometriosis was observed, particularly in cases of advanced endometriosis [44, 48, 50, 53, 54]; however, three other research groups reported no change in IL-4 and/or IL-10 in the serum and PF of endometriosis patients [56–58]. Inconsistencies may be due to differences in patient selection, such as whether the patients were infertile or not and whether there was...
Variation endometriosis subtypes (ovarian endometrioma, superficial peritoneal endometriosis, deep infiltrating endometriosis). Additionally, adolescents with endometriosis were reported to have significantly increased IL-4 in serum and PF, suggesting that IL-4 could be a potential biomarker for identifying endometriosis [47]. Furthermore, IL-10 promoter 592A/C and 819T/C polymorphisms have been reported to be associated with endometriosis risk in a Chinese population [51, 59], and considered to increase susceptibility to advanced endometriosis [43]. As a type of Th2 cytokine, IL-13 shares homology with IL-4, interacts with IL-4 receptor and attenuates monocyte/macrophage function (downregulates the production of TNF-α, IL-1 and IL-8 by monocytes) [60]. Chegini et al. have reported that IL-13 is elevated in the endometriotic endometrium and PF in patients with endometriosis [61]; however, no difference in IL-13 in the peripheral blood [14, 62] and PF [49, 63] was observed in endometriosis patients. Differences in the clinical staging of disease and the phases of the menstrual cycle in patients may be factors that cause the inconsistent conclusions among different studies.

Table 1 The change of anti-inflammatory cytokines in endometriosis

<table>
<thead>
<tr>
<th>Classification</th>
<th>Cytokine</th>
<th>Location</th>
<th>Change (EMS vs Control)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Th2 cytokine</td>
<td>IL-4</td>
<td>Peripheral blood</td>
<td>↑</td>
<td>[38–41, 47]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peritoneal fluid</td>
<td>↑</td>
<td>[44, 47, 48]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ectopic lesion</td>
<td>↑</td>
<td>[38, 39]</td>
</tr>
<tr>
<td>IL-10</td>
<td>Peripheral blood</td>
<td>↑</td>
<td>[40, 42–44, 46, 55]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>↑</td>
<td>[39, 46, 48–54]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>↑</td>
<td>[42, 45]</td>
<td></td>
</tr>
<tr>
<td>IL-13</td>
<td>Peripheral blood</td>
<td>NS</td>
<td>[14, 40, 62]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>NS</td>
<td>[49, 63]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>↑</td>
<td>[61]</td>
<td></td>
</tr>
<tr>
<td>Growth factor</td>
<td>TGF-β</td>
<td>Peripheral blood</td>
<td>↓</td>
<td>[46, 67]</td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>↑</td>
<td>[46, 48, 54, 74–77]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>↑</td>
<td>[45, 48, 68–73]</td>
<td></td>
</tr>
<tr>
<td>Innate cytokine</td>
<td>IL-25</td>
<td>Peripheral blood</td>
<td>↑</td>
<td>[97]</td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>IL-33</td>
<td>Peripheral blood</td>
<td>↑</td>
<td>[95]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>↑</td>
<td>[95]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>↑</td>
<td>[95, 96]</td>
<td></td>
</tr>
<tr>
<td>TSLP</td>
<td>Peripheral blood</td>
<td>↑</td>
<td>[94]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>↑</td>
<td>[94]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Other cytokines</td>
<td>IL-1RA</td>
<td>Peripheral blood</td>
<td>↑</td>
<td>[40, 98]</td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>↑</td>
<td>[99]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>IL-37</td>
<td>Peripheral blood</td>
<td>↑</td>
<td>[44, 58, 104]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peritoneal fluid</td>
<td>↑</td>
<td>[58, 104]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ectopic lesion</td>
<td>↑</td>
<td>[103]</td>
<td></td>
</tr>
</tbody>
</table>

NS, no significant difference; –, no data
Transforming growth factor (TGF-β)

TGF-β is a multifunctional growth factor that has important regulatory effects on many developmental and physiological processes. TGF-β was initially identified as a potent chemotactic cytokine that initiates inflammation and its overexpression mediates inflammation in the skin [64]; however, the severe and uncontrolled inflammatory reactions observed in the TGF-β knockout mouse indicated that the physiological role of TGF-β is predominantly as an anti-inflammatory cytokine [65]. Its immunosuppressive functions include the inhibition or reversal of macrophage activation, resulting in downregulated release of pro-inflammatory cytokines, and reactive oxygen and nitrogen species [66]. Numerous studies have confirmed that the levels of TGF-β are significantly higher in the peripheral blood [46, 67], ectopic endometrium (e.g., endometriotic cystic wall) [45, 48, 68–73] and PF [46, 48, 54, 74–77] of patients with endometriosis than in controls.

IL-25, IL-33, and thymic stromal lymphopoietin (TSLP)

The endogenous cytokines IL-25 (or IL-17E) [78–80], IL-33 [81, 82], and TSLP [83–86] have a role in the maturation of Th2 cells via dendritic cell activation. IL-25 [87–89], IL-33 [88, 89], and TSLP [89, 90] also induce activation of and IL-13 production from innate immune cells, including type 2 innate lymphoid cells. These cytokines have important regulatory roles in allergic diseases, such as asthma [89]. Previous studies have reported a higher prevalence of allergic disease among women with endometriosis [91, 92]. Type 1 allergies develop in a Th2 cytokine environment. Increasing evidence has shown that IL-33 and TSLP are increased in the peripheral blood [93–95], endometriotic endometrium [93–96], and PF [94] of patients with endometriosis. Notably, IL-33 and soluble ST2 (sST2) levels in PF or endometriotic lesions were correlated with endometriosis severity [95, 96]. However, Jaeger-Lansky et al. observed a similar level of IL-33 in the PF between endometriosis and control individuals [55]; however, it should be noted that the PF collected in this study was a mixture of free fluid in the recto-uterine pouch and fluid from genital organs washed with saline solution [55]. One study reported that levels of IL-25 are higher in PF from endometriosis patients; however, IL-25 levels were not correlated with disease stage [97]. Unfortunately, IL-25 levels in peripheral and endometriotic lesions were not analyzed in this study.

IL-1 receptor antagonist (IL-1RA) and IL-37

The IL-1 family is the largest family of interleukins, which comprises 11 members, including pro-inflammatory agonists (IL-1β, IL-18 and IL-36), and defined or putative antagonists (IL-1RA and IL-37) with anti-inflammatory activities. An elevated level of IL-1R was detected in serum [40, 98] and PF [98] from patients with endometriosis. Oppositely, Zhang et al. reported that there was a lower level of IL-1RA in PF from endometriosis patients, particularly those with dysmenorrhea [99]. This conflicting result may be due to the different criteria for patient selection used between the studies; for example, all patients in the former study were infertile [98]. IL-37 inhibits innate and adaptive immune functions by reducing the expression of pro-inflammatory cytokines (TNF-α, IL-6 and IL-17) [100, 101], and its suppressive effect on inflammatory factor may be mediated by inhibition of nuclear factor-kappa B (NF-κB) [102]. IL-37 was reported to be highly expressed in eutopic and ectopic endometrium of women with ovarian endometriosis, particularly ectopic endometrium [103]. In addition, IL-37 was elevated in peripheral blood [44, 58, 104] and PF [58, 104] from patients with endometriosis.

As the disease progresses, the levels of pro-inflammatory cytokines in PF and/or ectopic lesions gradually increase, while anti-inflammatory cytokines tend to increase in the later stage of the disease [39, 48, 50, 95, 98, 104–106]; however, there is still a lack of larger datasets that have measured the concentration of pro-inflammatory and anti-inflammatory cytokines in endometriosis. If large sample studies are conducted, the dynamic changes of these pro-inflammatory and anti-inflammatory cytokines in disease progression may be elucidated. Although pro-inflammatory and anti-inflammatory cytokines are reported to increase in the peripheral blood of endometriosis patients, researchers still question their diagnostic value for endometriosis [32, 33]. Similarly, their use for disease diagnosis requires further assessment in large sample studies.

Origin

Immune cell

Endometriotic lesions have a higher concentration of T lymphocytes than the eutopic endometrium [19, 107]. Foxp3-expressing CD4+ regulatory T cells (Tregs) are an important subset of T lymphocytes with a crucial role in the maintenance of self-tolerance and immune homeostasis, and are involved in various human diseases, such as autoimmune diseases and cancer [108–110]. As the two key functional cytokines, IL-10 and TGF-β are secreted by Tregs in ectopic lesions and PF, and are significantly increased in patients with endometriosis (Fig. 2) [54, 74, 77, 111–113]. As opposed to pro-inflammatory interferon (IFN)-γ+Th17 cells, IL-10 production by Th17 cells is critical for limiting autoimmunity and inflammatory responses. This unique subset
Anti-inflammatory cytokines in endometriosis

of Th17 cells simultaneously secretes IL-10 and IL-17A in the PF of women with endometriosis [48]. Macrophages are the most prevalent type of immune cells in the PF [114], and their number and activation [115], and their production of cytokines (such as IL-6, IL-10, IL-12 and TGF-β1) [77, 116] are increased in endometriosis. Co-culture of macrophages and endometrial stromal cells (ESCs) increases the production of IL-10 and TGF-β [48, 117–119] and further stimulates TGF-β secretion by Tregs [54, 113, 120]. As the classical allergy mediators, mast cells (MCs) are also present in high numbers in endometriotic lesions [121–123]. MCs and Th2 cells may be the most important sources of high IL-25 in PF [97]. Interestingly, a population of aryl hydrocarbon receptor-expressing MCs that express IL-17 and IL-10 has been recently identified in the endometrium [124]. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that have a major role in immunosuppression in cancer, inflammation and other diseases [125, 126]. Increased MDSCs have been confirmed in peripheral blood, PF and endometriotic lesions of endometriosis patients by several groups [127–130]. IL-10, GM-CSF and ARG1 are important effectors secreted by MDSCs; therefore, further studies are required clarify whether MDSC are also associated with the high IL-10 level in endometriosis.

**ESCs/endometrial epithelial cells (EECs)**

Immunohistochemical analysis has demonstrated that IL-4-positive cells accumulate around blood vessels in the stroma of endometriotic tissue [131]. IL-10 and TGF-β are highly expressed in ESCs [45, 48, 118, 119, 132] and EECs [72] from endometriotic endometrium, and EECs have been found to be the primary source of IL-13 expression [61]. Subsequently, the same research team confirmed that ESCs and EECs isolated from endometrium expressed IL-13 in primary culture [133], and TSLP is also produced and secreted by the isolated ESCs [94, 134, 135]. Our previous study demonstrated that endometriotic ESCs secrete high levels of IL-33 [118], which was further confirmed by a recent report [96]; however, no study has investigated the secretion of IL-25, IL-33 and TSLP by ECCs, which requires

---

**Fig. 2** Schematic presentation of cell population and the origin of anti-inflammatory cytokines in endometriotic milieu. PF peritoneal fluid
Endometriotic mesenchymal stem cells (MSCs)

The presence of regenerating healthy endometrial MSCs [136, 137], menstrual blood stromal stem cells (MenSCs) [138, 139] and endometriotic MSCs [139–142] has recently been reported, with the cell types exhibiting similar phenotypes. These endometrial MSCs are involved in the pathogenesis of endometriosis [139–142]. Reverse transcription-polymerase chain reaction analysis revealed that the anti-inflammatory cytokine TGF-β was significantly down-regulated and IL-10 was significantly increased in endometriotic MSCs [143]. Another group recently reported that endometriotic MSCs secrete high levels of TGF-β [144]. Additionally, MenSCs are another source of IL-10 in endometriosis [138].

Peritoneal mesothelial cells (PMCs)

In women with endometriosis, peritoneal areas adjacent to endometriosis lesions express higher TGFβ1 mRNA levels than distal sites [76]. Researchers also speculate that cells present in the peritoneum are a major source of IL-10 [50]. PMCs are the largest cell population within the peritoneal cavity. TGF-β1 protein is detectable in conditioned media from primary cultures of human peritoneal mesothelial cells (HPMCs) [76, 145], suggesting that the peritoneum, and in particular, the peritoneal mesothelium, is a source of TGF-β1, which is enhanced around endometriotic lesions [76, 146]. Shed menstrual tissue, ectopic endometrial cells and macrophages are thought to be additional sources of TGF-β1 present in the PF of women with endometriosis [147].

Platelets

Considering that ectopic endometrium experiences cyclical and repeated bleeding [148], a basic sign of tissue injury, Guo et al. recently reported that platelets have important roles in the development of endometriosis [149–151]. Activated platelets release TGF-β1 [152], and the activation of platelets in endometriosis is significantly higher than in controls [153]. Tanshinone IIA (Tan IIA) is a major lipophilic component extracted from the root of *Salvia miltiorrhiza* Bunge that can inhibit the function of platelets and the formation of thrombus [154, 155]. Immunohistochemical analysis has demonstrated that Tan IIA treatment significantly decreased TGF-β1 staining and platelet aggregation in ectopic endometrium [156]. Treatment of platelets with endometriotic ESCs increased the concentration of TGF-β1 in a density-dependent manner [157]. These results suggest that the increased activation of platelets is also an important source of TGF-β1 in endometriosis.

Function

**Immune escape**

Endometriotic lesions are detectable at a pathological stage, and it is extremely rare to be able to microscopically detect the earlier phases of attachment and proliferation of endometrial tissue in the peritoneum. Numerous studies have attempted to elucidate why ectopic implants develop resistance to scavenging by the immune system due to (at least in part) the altered function of macrophages, natural killer (NK) cells and T cells. It has been demonstrated that T cell reactivity and NK cytototoxicity are decreased in the PF of women with endometriosis, and an increase in the number and activation of peritoneal macrophages with impaired phagocytic activity has been reported [19].

An increase in CD4+CD25+ Tregs can suppress the proliferation of CD4+CD25− effector T cells [54]. As the two key cytokines secreted by Tregs, IL-10 and TGF-β1 are likely to be involved in this process [54]. Anti-inflammatory cytokines, IL-10 and TGF-β1, produced by endometriotic ESCs, macrophages and platelets can weaken the cytotoxic activity of NK cells, which is not due to increased NK cell apoptosis or decreased NK cell proliferation; it is caused by reduced expression of activating receptors, natural killer group 2 member D (NKG2D) and NK receptor (NKp46), reduced perforin production and increased expression of inhibitory receptor killer cell immunoglobulin-like receptor 2DL1 in NK cells [119, 158–160].

Additionally, endometriotic ESCs induce the differentiation of activated macrophages and reduce the phagocytic activity of macrophages in co-culture, which can be reversed by the addition of an IL-33 inhibitor, suggesting that IL-33 produced by endometriotic ESCs contributes to the reduced phagocytic ability of macrophages in endometriosis [118]. It has been reported that a decrease in ST2 suppresses breast cancer progression and metastasis in mice, mainly by via enhanced cytotoxic activity of NK cells [161]. These results suggest that IL-33 may reduce the cytotoxicity of NK cells during endometriosis. Thus, the functional changes induced by anti-inflammatory cytokines contribute to immunosurveillance evasion of ectopic endometrial cells.

Inflammation regulation

Pro-inflammatory and anti-inflammatory factors/responses antagonize each other to maintain physiological homeostasis and pathological immune imbalance. Mancini et al. reported that stimulation with 10 fg/ml IL-10 inhibits NF-κB p65
nuclear localization in endometriotic epithelial (12Z) cells and stromal (22B) cells; however, a marked change in IL-1β levels was not observed in vitro [162]. This study did not analyze the effects of IL-10 on the growth of ESCs and EECs further in vitro or in vivo. A recent study reported that IL-37 inhibits the expression of pro-inflammatory cytokines, IL-1β, IL-6 and TNF-α, and anti-inflammatory IL-10 in human ESCs in vitro [163]. Treatment of endometriosis model mice with recombinant human IL-37 reduced the size and weight of endometriotic-like lesions and reduced expression of IL-1β, IL-6, IL-10 and TNF-α in PF [163]; however, a limitation of this study was that human, not mouse, IL-37 was used in the animal experiments, which makes it unclear whether this result can accurately reflect the process in vivo. Currently, there is limited evidence that elevated anti-inflammatory cytokines in the late stage of disease can alleviate disease activity by controlling inflammation.

By contrast, Miller et al. reported that in vitro stimulation with IL-33 increased the production of pro-inflammatory cytokines, IL-1α and TNF-α, by human umbilical venule endothelial cells (HUVECs), and the production of chemokine (C-X-C motif) ligand 1 (CXCL1) and IL-6 by 12Z cells [96]. In a syngeneic mouse model of endometriosis, IL-33 injections caused an increase in pro-inflammatory cytokines within the plasma [96]. Therefore, an increase in anti-inflammatory cytokines in the later stage of the disease potentially has a dual role in the immune regulation of the endometriotic microenvironment. On one hand, the anti-inflammatory cytokines accelerate disease development by promoting immunosurveillance evasion of ectopic endometrial cells and inducing inflammation; and on the other hand, they reduce disease activation by restricting the inflammation. Further research is required.

**Cell proliferation, apoptosis, adhesion, migration and invasion**

Abnormal cellular characteristics (high proliferative ability, adhesion, migration and invasion, and low levels of apoptosis and autophagy) present in the endometrium of women with endometriosis contribute to ectopic survival and growth of endometrial tissue outside of the uterine cavity [164–171]. Research has revealed that IL-4 induces phosphorylation of p38 mitogen-activated protein kinase (MAPK), stress-activated protein kinase/c-Jun kinase and p42/44 MAPK, and that inhibitors of these kinases suppress IL-4-induced proliferation of human endometriotic ESCs in vitro [172]. Blocking IL-4 significantly reduces the number and volume of total ectopic lesions, downregulates the expression of integrinβ1, matrix metalloproteinase (MMP)-3, MMP-9, E-cadherin and β-catenin in ectopic lesions, and inhibits the development of endometriosis in a syngeneic mouse model [173]. These findings suggest that proliferation, growth adhesion and invasion of endometriotic endometrium induced by locally produced IL-4 are involved in the development of endometriosis.

Suen et al. [42] demonstrated that depletion of IL-10 activity in a mouse model of surgically induced endometriosis significantly decreased the size of endometrial lesions, which supported the findings of an earlier report [174]. Subsequent research revealed that the secretion of IL-10 and TGF-β1 by Tregs increased MMP-2 expression and decreased tissue inhibitor of metalloproteinase 1 (TIMP1) expression. IL-10 and TGF-β1 secretion also stimulated the proliferation and invasion of ESCs in vitro, and the growth of ectopic lesions in vivo [54, 175]. Additionally, IL-10 can cooperate with IL-17A to promote growth, adhesion, invasion and implantation of endometriotic ESCs, and reduce apoptosis in vitro and in vivo [48]. Compared with blocking IL-10 or IL-17A alone, the anti-endometriosis effect is improved by simultaneously blocking IL-10 and IL-17A [48].

In addition to the decrease of immune cell activity, studies in mice and women have indicated that increasing levels of TGF-β1 are associated with an increase in ectopic endometrial cell survival, attachment, invasion, and proliferation, during endometriosis lesion development [146, 176]. Bristol-Gould et al. [177] have developed a mouse model of ovarian endosalpingiosis and found that the onset of this disease is dependent on TGF-β/activin/mothers against decapentaplegic homolog 2 (also known as SMAD family member 2 or Smad2). Treatment with a TGF-β type 1 receptor (TGFβR1) inhibitor can diminish disease progression in mice, especially when used synergistically with a histone acetyltransferase inhibitor [178]. In vitro experiments revealed that TGF-β1 can enhance integrin-mediated cell–cell adhesion by activating the Smad signaling pathway [71, 72, 179] and promoting attachment of cells to the HMrSV5 (human peritoneal mesothelial cell line) cell monolayer, and increase the Matrigel invasion of ESCs, potentially by upregulating the expression of Versican V1 [180]. Most interestingly, treatment of endometriotic EECs and normal EECs with TGF-β1 dramatically increases Smad-dependent and TGFβR1-dependent secretion of plasminogen activator inhibitor-1 (PAI-1) in these cells. Recombinant PAI-1 can increase cellular de-adhesion of endometriotic EECs and normal EECs [132], suggesting that TGF-β1 regulates peritoneal wound repair, and the dynamic imbalance between adhesion formation and de-adhesion of endometriotic cells in endometriosis [176] TGFβR1 expression is significantly higher in the high-migratory ectopic endometriotic tissues, and wound-closure assay, transwell assay and confocal imaging of F-actin cellular distribution have further demonstrated that TGF-β1 significantly increases the migration ability of endometriotic ESCs by upregulating the expression of octamer-binding transcription factor Suen et al. [42] demonstrated that depletion of IL-10 activity in a mouse model of surgically induced endometriosis significantly decreased the size of endometrial lesions, which supported the findings of an earlier report [174]. Subsequent research revealed that the secretion of IL-10 and TGF-β1 by Tregs increased MMP-2 expression and decreased tissue inhibitor of metalloproteinase 1 (TIMP1) expression. IL-10 and TGF-β1 secretion also stimulated the proliferation and invasion of ESCs in vitro, and the growth of ectopic lesions in vivo [54, 175]. Additionally, IL-10 can cooperate with IL-17A to promote growth, adhesion, invasion and implantation of endometriotic ESCs, and reduce apoptosis in vitro and in vivo [48]. Compared with blocking IL-10 or IL-17A alone, the anti-endometriosis effect is improved by simultaneously blocking IL-10 and IL-17A [48].

In addition to the decrease of immune cell activity, studies in mice and women have indicated that increasing levels of TGF-β1 are associated with an increase in ectopic endometrial cell survival, attachment, invasion, and proliferation, during endometriosis lesion development [146, 176]. Bristol-Gould et al. [177] have developed a mouse model of ovarian endosalpingiosis and found that the onset of this disease is dependent on TGF-β/activin/mothers against decapentaplegic homolog 2 (also known as SMAD family member 2 or Smad2). Treatment with a TGF-β type 1 receptor (TGFβR1) inhibitor can diminish disease progression in mice, especially when used synergistically with a histone acetyltransferase inhibitor [178]. In vitro experiments revealed that TGF-β1 can enhance integrin-mediated cell–cell adhesion by activating the Smad signaling pathway [71, 72, 179] and promoting attachment of cells to the HMrSV5 (human peritoneal mesothelial cell line) cell monolayer, and increase the Matrigel invasion of ESCs, potentially by upregulating the expression of Versican V1 [180]. Most interestingly, treatment of endometriotic EECs and normal EECs with TGF-β1 dramatically increases Smad-dependent and TGFβR1-dependent secretion of plasminogen activator inhibitor-1 (PAI-1) in these cells. Recombinant PAI-1 can increase cellular de-adhesion of endometriotic EECs and normal EECs [132], suggesting that TGF-β1 regulates peritoneal wound repair, and the dynamic imbalance between adhesion formation and de-adhesion of endometriotic cells in endometriosis [176] TGFβR1 expression is significantly higher in the high-migratory ectopic endometriotic tissues, and wound-closure assay, transwell assay and confocal imaging of F-actin cellular distribution have further demonstrated that TGF-β1 significantly increases the migration ability of endometriotic ESCs by upregulating the expression of octamer-binding transcription factor.
endometriosis. TGF-β signal blockade using a TGFβRI inhibitor, A83-01, fully attenuates the platelet-induced cell migratory and invasive propensity of endometriotic ESCs in vitro [182]. Moreover, TGF-β1 significantly induces the expression of colony stimulating factor 1 receptor (c-fms) mRNA and c-fms cell-surface expression, and enhances transmesothelial invasion by EM42 cells (an immortalized EEC line) and primary EECs in a three-dimensional in vitro model of the peritoneum [183]. However, cellular proliferation and attachment of EECs to PMCs were not influenced by TGF-β1 [183].

In a syngeneic mouse model of endometriosis, injection with IL-33 caused an increase in the proliferation of endometriotic lesions [96]. TSLP stimulates the production of cytokines chemokine (C–C motif) ligand 2 (CCL2) and IL-8 (also known as CXCL8) by ESCs, and promotes the growth of ESCs via c-Jun N-terminal kinase (JNK) and NF-κB signaling pathways in vitro [134]. Notably, endometrial tissue conditioned media enhances the adhesive capability of human endometriotic tissues in mice, and co-treatment with IL-1RA dramatically reduces this effect [184]; however, the role of other anti-inflammatory cytokines, IL-13 and IL-25, in the regulation ESC and EEC biological functions requires further study.

As described above, these anti-inflammatory cytokines can promote the ectopic growth, adhesion, and implantation of ESCs, and even cooperate with pro-inflammatory cytokines to form a local cytokine regulation network and further accelerate the origin and progression of endometriosis.

**Epithelial-mesenchymal transition (EMT), mesothelial-to-mesenchymal transition (MMT), fibroblast-to-myofibroblast transdifferentiation (FMT), smooth muscle metaplasia (SMM) and fibrogenesis**

EMT is a process by which epithelial cells lose polarized organization of the cytoskeleton and cell-to-cell contacts, acquiring the high motility that is characteristic of MSCs. These changes are thought to be prerequisites for the original establishment of endometriotic lesions [185, 186]. In human endometriotic ESCs, TGF-β1 dose-dependently increases the gene and protein levels of OCT4, SNAIL and N-cadherin, and silencing of endogenous OCT4 significantly suppresses these TGF-β1-induced effects. This demonstrates that TGF-β1, in co-operation with OCT4, contributes to the process of EMT in endometriosis [181]. Matsuzaki et al. [187] demonstrated that stimulation with TGF-β1 initiates a partial EMT-like process in EECs grown on polyacrylamide gel substrates (a soft matrix). Additionally, TGF-β1 has long been regarded as a major regulator of fibrosis [176, 185, 188, 189]; for example, long-term TGF-β1 stimulation induces phosphorylation of nuclear receptor subfamily 4 group A member 1 in a protein kinase B (also known as AKT)-dependent manner, which then promotes the expression of fibrotic markers in vitro and stimulates fibrogenesis in mice with endometriosis [190]. Endometriotic MSCs significantly promote fibrogenesis in ovarian endometrioma through the Wnt/β-catenin pathway via paracrine production of TGF-β1 and Wnt1 [144]. Notably, activated platelets, promote EMT and FMT in endometriosis through the release of TGF-β1, resulting in the increased cell contractility, collagen production, and, ultimately, fibrosis [182]. Exposure of endometriotic ESCs to activated platelets induces the increased expression of alpha smooth muscle actin (α-SMA) and markers of differentiated smooth muscle cells [182]. SMM has been frequently observed in peritoneal, ovarian, extragenital, and pleuropulmonary endometriosis [191]. Another common process in peritoneal fibrotic tissue is MMT, by which mesothelial cells in the peritoneal cavity transform into myofibroblasts under pathological conditions. In a mouse model, blockade of TGF-β resulted in molecular reprogramming of markers associated with the mesenchymal conversion of mesothelial cells and a significant decrease in the severity of peritoneal adhesions [192].

Although there are no reports regarding the role of other anti-inflammatory cytokines (e.g., IL-4 and IL-10) in EMT and FMT during endometriosis, a large number of studies have demonstrated that IL-4 [193], IL-10 [194], IL-13 [195], and IL-33 [196] promote EMT in cancer cells and human kidney cells. Anti-inflammatory cytokine IL-4 and pro-inflammatory cytokine IL-17A provide a Th2/Th17-polarized inflammatory environment, in which TGF-β1 induces bronchial and alveolar EMT processes [193, 197, 198]; however, IL-37 decreases the EMT of lung cancer cells by inhibiting IL-6 expression [199]. Serum IL-33 concentration is positively correlated with leiomyoma features, such as fibroid weight and size, and the number of fibroids [200]. Additionally, IL-13 [201] promotes liver fibrosis, and IL-10 inhibits fibrosis [202]. The reports discussed indicate that the aforementioned anti-inflammatory cytokines, together with TGF-β1, may participate in the regulation of EMT, MMT, FMT and SMM in endometriosis, and pro-inflammatory cytokines may also have a synergistic role in these effects, which is worth further attention and research.

**Angiogenesis**

Angiogenesis is a key process involved in the successful establishment and growth of endometriotic lesions [203, 204]. Immunohistochemical analysis has shown that eotaxin-positive cells colocalize with IL-4-positive cells and accumulate around the blood vessels in the stroma of endometriotic tissue. IL-4 can increase secretion of eotaxin...
from ESCs and may further promote angiogenesis, and the subsequent development of endometriosis [131, 205]. In contrast, blocking IL-4 leads to the reduced expression of vascular endothelial growth factor (VEGF) in the endometriotic lesions of mice and may further impair vascularization of the ectopic endometrium [173]. Interestingly, VEGF and IL-10 concentrations are positively correlated in the PF of endometriosis patients, but IL-10 neutralizing antibody did not affect the release of VEGF by neutrophils treated with PF from patients with endometriosis [206].

Yong et al. reported that TGF-β1 can upregulate VEGF-A expression in PMCs by increasing expression of inhibitor of DNA binding (ID) 1 [207]. The luciferase activity of a VEGF promoter construct was increased in the presence of either TGF-β1 or hypoxia, and combined treatment with hypoxia and TGF-β1 resulted in a much higher production of VEGF by ESCs [70]. Furthermore, TGF-β1 and pro-inflammatory cytokines, IL-1β or TNF-α, can synergistically promote IL-8 and VEGF expression in ESCs via the p38/extracellular-signal-regulated kinase (ERK) 1/2 signaling pathways, and stimulate the angiogenesis of HUVECs in vitro [120]. As mentioned above, TGF-β1 has been associated with changes in ectopic endometrial and peritoneal cell metabolism, and the initiation of neoangiogenesis and endometriosis lesion development [146].

In vitro studies have shown that stimulation with IL-33 significantly increases the levels of angiogenic factors, including VEGF and platelet-derived growth factor-AA, by EECs and stimulates tubulogenesis in HUVECs [96]. Endometriotic lesions from IL-33-treated mice were highly vascularized and exhibited increased proliferation of endometriotic lesions, which echoed the results discussed above [96]. IL-8 is considered to be an important angiogenic factor [208]. As previously described, TSLP upregulates the production and secretion of IL-8 from ESCs in vitro [134]. It has also been established that TSLP secreted by cervical cancer cells stimulates proliferation, activation and angiogenesis of HUVECs, but does not alter HUVEC apoptosis in vitro [209]. Therefore, it is likely that TSLP has a role in angiogenesis associated with endometriosis, with further studies required to confirm this function.

**Others**

It has been reported that elevated serum IL-33 is correlated with the intensity of painful pre-operative symptoms, and with the extent and severity of deeply infiltrating endometriosis [93]. Alterations in Treg and NK cell-related cytokines are associated with deep infiltrating rectosigmoid endometriosis, and TGF-β1, IL-7 and IL-15 expression is linked to dyspareunia, dysmenorrhea and cyclic dyschezia in patients with endometriosis [45]. However, the regulatory roles and molecular mechanisms of IL-33 and TGF-β1 in endometriosis-related pain are almost entirely unknown.

Prostaglandin E2 (PGE2) stimulates P450 aromatase (P450arom) expression in ESCs and increases the production of estrogens [210]. IL-4 was shown to have no effect on the expression of P450arom mRNA, whereas IL-4 and PGE2 in combination significantly augmented the production of estrone from dehydroepiandrosterone (DHEA) in vitro. These findings suggest that the combination of IL-4 and PGE2 may enhance estrogen production in endometriotic tissues, suggesting a complex mechanism exists whereby Th2 immune responses augment inflammation-dependent estrogen production, which promotes disease progression [211].

**Regulation**

**Chemokines**

Chemokines produced in the endometriotic microenvironment contribute to a feed-forward cascade of events, which promote the recruitment of leukocytes to the peritoneal cavity and regulate the proliferation and invasion of ESCs in patients with endometriosis. These chemokines include regulated on activation, normal T cell expressed and secreted (RANTES; also known as CCL5), CCL2, CXCL8 and thymus-expressed chemokine (also known as CCL25) [212–215]. As depicted in Table 2, under the regulation of 17β-estradiol (E2) and dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), RANTES secreted by ESCs can increase macrophage recruitment, and induce tolerant phenotypes by upregulating IL-10 and downregulating IL-23. In turn, these macrophages inhibit apoptosis and enhance the growth of ESCs [117]. Subsequently, our studies show that ESC-derived CCL25 enhances the production and secretion of IL-10 and TGF-β in Tregs by activating the AKT/signal transducer and activator of transcription 3 (STAT3) signaling pathway [54]. Treatment with CCL25 also enhances IL-10 secretion by CD33+CD14+CD11b+HLA-DR+ monocyteic MDSCs (M-MDSCs) in vitro [129]. Taken together, these findings indicate that chemokines are involved in the regulation of anti-inflammatory cytokines in the endometriotic environment.

**Pro-inflammatory cytokines**

It has been reported that the pro-inflammatory cytokine IL-1β significantly increases the secretion of IL-4 [216]. In addition, IL-1β contributes to the Th2 immune response by promoting the secretion of TSLP, and this effect is dependent on p42/44 MAPK, p38 MAPK and stress-activated protein kinase (SAPK)/INK signaling pathways [94]. IL-4...
<table>
<thead>
<tr>
<th>Classification</th>
<th>Regulatory factor</th>
<th>Function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemokine</td>
<td>RANTES</td>
<td>Recruits more macrophages and induces them into tolerant phenotype by upregulating IL-10 and downregulating IL-23</td>
<td>[117]</td>
</tr>
<tr>
<td></td>
<td>CCL25</td>
<td>Enhances the production and secretion of IL-10 and TGF-β1 in Tregs and M-MDSCs</td>
<td>[54, 129, 212]</td>
</tr>
<tr>
<td>Proinflammatory cytokine</td>
<td>IL-1β</td>
<td>Increases the secretion of IL-4</td>
<td>[216]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Contributes to the Th2 immune response by improving the secretion of TSLP</td>
<td>[94]</td>
</tr>
<tr>
<td></td>
<td>TNF-α</td>
<td>Increases the secretion of IL-13</td>
<td>[133]</td>
</tr>
<tr>
<td></td>
<td>IFN-γ</td>
<td>Inhibits the IL-1β-induced TSLP secretion from ESCs</td>
<td>[94]</td>
</tr>
<tr>
<td></td>
<td>IL-33</td>
<td>Upregulates the levels of IL-10 and TGF-β1 in macrophages in co-culture unit</td>
<td>[118]</td>
</tr>
<tr>
<td></td>
<td>IL-27</td>
<td>Induces IL-10 production of Th17 cells</td>
<td>[48]</td>
</tr>
<tr>
<td></td>
<td>IL-8 and IL-23</td>
<td>Induces the differentiation of COX-2&lt;sup&gt;high&lt;/sup&gt;CD16&lt;sup&gt;−&lt;/sup&gt;NK cells with high levels of IL-10 and TGF-β1</td>
<td>[217]</td>
</tr>
<tr>
<td>Hormone/hormonal drugs</td>
<td>17β estradiol</td>
<td>Regulates GATA3 and promotes Th2 cytokines expression of EECs</td>
<td>[221, 222]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulates the secretion of TSLP by ESCs</td>
<td>[134, 135, 223]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Induces IL-10 production of Th17 cells by promoting IL-27 from macrophages and ESCs</td>
<td>[48]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Results in a rapid induction of IL-13 and IL-15 expression in ESCs and EECs but not a sustained induction</td>
<td>[133]</td>
</tr>
<tr>
<td></td>
<td>Urocortin</td>
<td>Urocortin 2 increases TNF-α and IL-4 while urocortin 3 induces an increase of IL-4 secretion</td>
<td>[228]</td>
</tr>
<tr>
<td></td>
<td>GnRH analogs</td>
<td>Inhibits IL-1, IL-2, IL-8, and IL-13 levels in the serum with recombinant IL-2</td>
<td>[233]</td>
</tr>
<tr>
<td></td>
<td>Danazol</td>
<td>Suppresses IL-2 and interferon-γ were but upregulates IL-4 and IL-10 and increases Tregs population among splenocytes</td>
<td>[235, 236]</td>
</tr>
<tr>
<td>Non-steroidal drugs</td>
<td>Macrolide</td>
<td>Increases IL-10 expression in the rat endometriosis model</td>
<td>[237]</td>
</tr>
<tr>
<td></td>
<td>PLGA/anti-CTLA-4</td>
<td>Downregulates IL-10 and TGF-β secreted by Tregs</td>
<td>[175]</td>
</tr>
<tr>
<td></td>
<td>Sodium TAN IIA sulfonate</td>
<td>Reduces the expression of CD4&lt;sup&gt;+&lt;/sup&gt;, TGF-β1, p-Smad3, α-SMA and collagen I in ectopic lesions</td>
<td>[156]</td>
</tr>
<tr>
<td></td>
<td>G-Rg3</td>
<td>Decreases mRNA levels of Ki-67, fibronectin, TGF-β1, MMP2 and MMP9 significantly in human ESCs</td>
<td>[245]</td>
</tr>
<tr>
<td></td>
<td>PPD</td>
<td>Activates the cytotoxicity and decreases IL-10 production of NK cells in endometriotic milieu</td>
<td>[246]</td>
</tr>
<tr>
<td></td>
<td>EGCG</td>
<td>Decreases the TGF-β1-dependent increase in the mRNA expression of fibrotic markers</td>
<td>[188]</td>
</tr>
<tr>
<td>Metabolite/metabolic enzyme</td>
<td>SNAP</td>
<td>Decreases plasma IL-2, IFN-γ, and IL-4 and increases IL-10, and enables the growth of implant in a murine model of endometriosis</td>
<td>[256]</td>
</tr>
<tr>
<td></td>
<td>IDO1</td>
<td>Triggers macrophages to display the tolerant cytokine profile (the markedly raised level of IL-10 and TGF-β1 and depressed level of IL-12p70) by upregulating IL-33 in ectopic ESCs</td>
<td>[118]</td>
</tr>
<tr>
<td></td>
<td>1-MT</td>
<td>Decreases differentiation of Treg cells in an ESC-Tregs co-culture unit, especially IL-10&lt;sup&gt;+&lt;/sup&gt; Treg cells</td>
<td>[113]</td>
</tr>
<tr>
<td></td>
<td>Glucose</td>
<td>Triggers production of TGF-β1 which plays a pivotal role in the progression of peritoneal fibrosis by inducing numerous pro-fibrotic events</td>
<td>[259]</td>
</tr>
<tr>
<td></td>
<td>LXA4</td>
<td>Induces TGF-β1 production in HPMCs in vitro</td>
<td>[145]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Downregulates the pro-inflammatory cytokines IL-1β and IL-6, as well as modulating TGF-β isoform expression within endometriotic lesions and in peritoneal fluid cells</td>
<td>[264]</td>
</tr>
<tr>
<td></td>
<td>Platelet</td>
<td>Increases concentration of TXB&lt;sub&gt;2&lt;/sub&gt;, thrombin, and TGF-β1</td>
<td>[157, 182]</td>
</tr>
</tbody>
</table>
enhances the IL-1β-induced TSLP secretion from ESCs, while IFN-γ inhibits it [94]. Roberts et al. [133] confirmed that primary ESCs and EECs isolated and cultured from endometrium express IL-13. Pro-inflammatory cytokine TNF-α and anti-inflammatory cytokine TGF-β1 both significantly increase the secretion of IL-13 from EECs and ESCs in vitro. Our previous study demonstrated that IL-33 derived from ESCs can upregulate the levels of IL-10 and TGF-β1 in macrophages in a co-culture [118], and IL-27 secreted by ESCs and macrophages induces IL-10 production by Th17 cells in the endometriotic environment [48]. IL-8 and IL-23 produced from ectopic lesions induce the differentiation of cyclooxygenase (COX)-2highCD16−NK cells, which express high levels of IL-10 and TGF-β1 [217]. As stated previously, there are interactions between pro-inflammatory (e.g., IL-1β, TNF-α, and IFN-γ) and anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-13, IL-33, TGF-β, and TSLP) in the microenvironment of ectopic lesions. The co-existence of high levels of pro-inflammatory and anti-inflammatory cytokines is involved in immune escape by endometriotic lesions and inflammation regulation.

**Hormones and hormonal drugs**

It is generally established that endometriosis is an estrogen-dependent disease [218]. Endometriotic lesions are associated with hormonal imbalance, including an increase in estrogen synthesis, metabolism and progesterone resistance. As a Th2 cell-specific transcription factor, the binding sites for GATA binding protein-3 (GATA-3) are present in the promoter regions of all Th2 cytokines [219]. This can promote differentiation of Th2 cells and induce the expression of Th2 cytokines, such as IL-4 and IL-10 [220]. GATA-3 is time- and dose-dependently regulated by E2, and promotes Th2 cytokine expression (e.g., IL-4 and IL-10) by EECs [221], which is consistent with previous evidence of the stimulatory regulation role of E2 in rat IL-10 expression [222]. In addition, E2 stimulates the secretion of TSLP by ESCs in a dose-dependent manner [134, 135, 223]. Under external (TCDD) and local (high levels of estrogen, IL-6 and TGF-β) environmental regulation, IL-27 secreted by macrophages and ESCs induces IL-10 production by Th17 cells in endometriosis in vitro and in vivo [48]. Treatment of EECs and ESCs with E2 and medroxyprogesterone acetate (MPA) results in a rapid induction of IL-13 and IL-15 expression [133]. Interestingly, prolonged MPA exposure, especially > 10 days, does not lead to a sustained induction of IL-13 and IL-15 [133]. These studies indicate that estrogen and MPA may indirectly contribute to the regulation of immune and endometriotic lesion implantation and growth by modulating these anti-inflammatory cytokines, and the potential mechanisms involved require further research.

The presence of neuroendocrine cells in the eutopic endometrium of women with endometriosis has been reported [224]. There is evidence that corticotrophin-releasing hormone [225] and urocortin [226] are present in endometriotic tissue, and that the levels of these neuropeptides are dysregulated in endometriosis [227]. Stimulation of cultured ESCs with urocortin 2 significantly increases TNF-α and IL-4, while urocortin 3 induces an increase in IL-4 secretion in vitro [228]. These results indicate that these neuropeptides may also be involved in the pathogenesis of endometriosis via the regulation of pro-inflammatory and anti-inflammatory cytokines.

Therapy with gonadotropin-releasing hormone (GnRH) analogs is effective for pain control in women with symptomatic endometriosis and has been considered the gold standard treatment for two decades. Currently, GnRH analogs are second-line therapy, when primary treatments fail, are contraindicated or are not tolerated [229–231]. Post-surgical treatment with GnRH analogs may be useful in reducing pain and in delaying recurrence of symptoms in patients with incomplete treatment [232]. Velasco et al. [233] found that patients receiving GnRH analogs alone had high IL-1, IL-2, IL-8 and IL-13 levels in their serum; however, administration of recombinant IL-2 plus GnRH analogs had a tendency to reduce cytokine production. Whether the anti-endometriosis effect of GnRH analogs depends on the regulation of these cytokines is unknown.
Danazol (the synthetic androgen 2,3-isoxazol), a derivative of 17α-ethynyl testosterone, has mild androgenic and strong anti-estrogenic activity. It can inhibit gonadotropin release, determine the competitive inhibition of steroidogenic enzymes, suppress cell proliferation, modulate immunologic function and reduce endometriosis-associated pain [231, 234]. In a murine model, danazol treatment significantly prolonged the survival of fully mismatched cardiac allografts. Furthermore, in danazol-treated mice, IL-2 and IFN-γ were suppressed, whereas IL-4 and IL-10 were upregulated in splenocytes, and the splenocyte Treg population was increased [235, 236]. However, whether danazol regulates the level of pro-inflammatory and anti-inflammatory cytokines in the endometriotic environment requires further investigation.

**Non-steroidal drugs**

As the pathogenesis of endometriosis involves immune responses, the immunomodulatory effect of macrolides has been a research focus. Clarithromycin and telithromycin increase IL-10 expression in rat endometriosis lesions induced by autotransplantation of endometrium, and also inhibit the growth of endometriotic lesions [237]; however, the mechanism needs further study.

Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is essential for the suppressive function of Tregs. Poly lactic-co-glycolic acid (PLGA) encapsulation of CTLA-4 antibody (PLGA/anti-CTLA-4) as a protein delivery vehicle exhibited superior potential as an endometriosis treatment in a mouse model compared to CTLA-4 antibody used alone. Most strikingly, in an in vitro experiment, PLGA/anti-CTLA-4 inhibited the proliferation and invasion of ectopic ESCs in a co-culture system, and downregulated IL-10 and TGF-β1 secretion by Tregs [175]. However, there is no clear evidence that CTLA-4 antibody regulates cytokine levels and has anti-endometriosis activity in vivo.

Tanshinone (TAN) is a pharmacologically active diterpenoid extracted from the roots of S. miltiorrhiza Bunge (a plant used in traditional Chinese medicine as a remedy for ‘blood stasis’, which is a term used in traditional Chinese medicine to describe hypercoagulability). TAN can inhibit platelet aggregation [238], and suppress TGF-β1/Smad3 and NF-kB signaling pathways, thus reducing fibrogenesis [239, 240]. Recent research has reported that sodium TAN IIA sulfonate injection significantly reduces the levels of CD41, TGF-β1, p-Smad3, α-SMA and collagen I in ectopic lesions, inhibits EMT, FMT, SMM and fibrogenesis, and reduces lesion weight in mouse endometriosis models [156]. However, large-scale clinical studies are required to assess the clinical value of TAN as an anti-endometriosis therapy.

As a traditional medicinal herb, ginseng is widely used in Asian countries and North America. Ginsenosides, such as ginsenoside-Rg3 (G-Rg3), G-Rf and G-Rh2, are the main components extracted from ginseng and have various pharmaceutical activities, including anti-oxidant, immunomodulatory, anti-inflammatory and anti-tumor effects [241, 242]. As two metabolites of ginsenoside, protopanaxadiol (PPD), and protopanaxatriol also exhibit similar activities [242–244]. Recent studies have shown that G-Rg3, G-Rf and PPD have powerful anti-endometriosis activities [245–248]. G-Rg3 reduces the proliferation, invasion and fibrosis of endometriosis. In vitro, the mRNA levels of Ki-67, fibronectin, TGF-β1, MMP-2 and MMP-9 were significantly decreased by G-Rg3 treatment in human ESCs [245]. In vivo, G-Rg3A reduced the size and fibrosis of mouse endometrial lesions [227], and inhibited angiogenesis in rat endometrial lesions [247]. G-Rf decreases the volume of the endometriotic implants, and writhing responses, endometriosis-associated dysmenorrhea and inflammation in a surgically induced rat endometriosis model [248]. PPD has anti-estrogen receptor α (ERα) effects, and induces the autophagy of ESCs, activates cytotoxicity and decreases IL-10 production by NK cells in a human ESC-NK co-culture model [246]. However, the clinical evidence of the anti-endometriosis effect of ginsenosides is still limited.

Epigallocatechin-3-gallate (EGCG) is one of the most abundant polyphenols present in green tea. It has been reported that EGCG reduces the size of endometriotic implants by inhibition of cell proliferation, angiogenesis, and induction of apoptosis in mouse endometriotic implants [249–252]. Furthermore, EGCG treatment significantly decreased the TGF-β1-induced in the mRNA expression of fibrotic markers, and the TGF-β1-stimulated activation of MAPK and Smad signaling pathways in endometriotic ESCs, suggesting that anti-fibrosis activity of EGCG may be dependent on the suppression of TGF-β1 in endometriosis [188]. However, there is no epidemiological evidence of a link between green tea consumption and the occurrence and treatment of endometriosis.

**Metabolite and metabolic enzyme**

Oxidative stress has been identified in the peritoneal cavity of women with endometriosis [253]. Nitric oxide (NO) is associated with chronic pelvic pain experienced by patients with endometriosis [254]. NO also has an important role in the regulation of local immune responses [255]. Intraperitoneal injections of S-nitroso-N-acetyl-penicillamine (SNAP), an NO donor, decreased plasma IL-2, IFN-γ and IL-4, increased IL-10 and enabled the growth of implants in a murine model of endometriosis [256].

Indoleamine 2,3-dioxygenase-1 (IDO1) is highly expressed in ectopic endometrium, and it can enhance the proliferation and invasion of ESCs in via an indirect immune regulation-independent mechanism [257] and
directly [113, 118, 258]. Additionally, IL-33 upregulated by IDO1 in ectopic ESCs can trigger macrophages to have a tolerant cytokine profile (with markedly increased IL-10 and TGF-β1 levels, and a reduced level of IL-12p70) [118]. In turn, these macrophages promote the proliferation and invasion of ESCs [258]. Interestingly, ESC-derived TGF-β1 also upregulates IDO levels in NK cells in co-culture [160]. A specific inhibitor of IDO1, 1-methyl-tryptophan (1-MT), decreases differentiation of Treg cells in an ESC-Treg co-culture, particularly IL-10+ [113]. Additionally, the total number and weight of mouse endometriotic lesions was notably decreased in a group of mice that received 1-MT [113].

Glucose is used as an osmotic agent in peritoneal dialysis solution, but glucose-based solutions are associated with increases in cytokines. For example, glucose-mediated production of TGF-β1 has a pivotal role in the progression of peritoneal fibrosis by inducing numerous pro-fibrotic events, such as EMT, fibroblast proliferation and extracellular matrix protein deposition [259]. Furthermore, high glucose can also induce TGF-β1 production in HPMCs in vitro, and silencing of FBJ murine osteosarcoma viral oncogene homolog (FOS) expression can significantly weaken this effect [145]. These studies discussed above suggest that high glucose may affect the immune status of the ectopic lesion microenvironment. It has been found that the prevalence of diabetes in women with endometriosis is similar to that of the general population [260]. However, Wang et al. reported that long-term hyperestrogenemia and type II diabetes increased the risk of malignant transformation of endometriosis in rats [261]; however, whether this is associated with changes in immune regulation caused by high glucose is unknown.

Lipoxins are endogenous eicosanoids predominantly produced via a transcellular biosynthetic pathway that have both anti-inflammatory and pro-resolving properties [262]. Lipoxins are estrogenic in vitro and in vivo as they can bind to ERα in EECs and counteract E2-mediated responses [263]. Lipoxin 4 (LXA4) treatment significantly reduces endometriotic lesion size, downregulates pro-inflammatory cytokines, IL-1β and IL-6, and modulates TGF-β isoform expression within endometriotic lesions and in PF cells [264]. However, it is unclear whether the regulation of these cytokines by LXA4 is involved in the inhibition of endometriotic lesion growth.

Secretion of thrombin and thromboxane A2 (TXA2) by ESCs can induce platelet activation and aggregation. Meanwhile, treatment of platelets further increased the concentration of TXB2, thrombin and TGF-β1 [157, 182]. These findings establish that there is a crosstalk between endometriotic lesions and platelets via thrombin and TXA-dependent mechanisms, which potentially contributes to the upregulation of TGF-β1 in endometriosis.

**Others**

Mannose receptor C, type 2 (MRC2) expression was notably decreased in ectopic ESCs, which negatively regulates Treg differentiation in ectopic lesions, particularly that of TGF-β1+ Tregs [113]. These results indicate that an estrogen-IDO1-MRC2 axis is involved in the differentiation and TGF-β1 production of Tregs, and is associated with the development of endometriosis by promoting immune escape of ectopic lesions. Immunohistochemistry analysis of human tissues has shown that TGF-β1 exhibits the same expression trend as hypoxia-inducible factor (HIF)-1α in ESCs and EECs, with the highest staining observed in ectopic lesions. Additionally, hypoxia increases TGF-β1 expression by ESCs in endometriosis [179]. Recombinant human TNF-binding protein-1 negatively modulates the expression of TGF-β1 in endometriotic lesions from baboons [265]. Furthermore, the Sp/Kruppel-like factor (KLF) family transcription factor, KLF11, can bind to specific elements located in the promoter regions of key fibrosis-related genes of the collagen, MMP and TGF-β1 families in ESCs, resulting in transcriptional repression of these genes [266]. Further research is required to analyze the underlying mechanism.

**Conclusions and future perspectives**

Chronic inflammation has an important role in the onset and development of endometriosis, particularly at the early stages. Therefore, it is often stated that endometriosis is an inflammatory disease from the immunological point of view; however, studies have also shown that anti-inflammatory cytokines produce by various cell types (e.g., immune cells, ESCs, EECs, MSCs, peritoneal mesothelial cells, and platelets) accumulate in the microenvironment of ectopic lesions. A lack of knowledge regarding the cytokine regulatory changes from the perspective of disease progression and role of anti-inflammatory factors in the local environment of endometriosis has led to less awareness and acceptance of the importance of anti-inflammatory factors in the pathogenesis of endometriosis. With the continuous research advances and in-depth studies, it can be concluded that anti-inflammatory cytokines also have a critical role in accelerating the growth, adhesion, invasion, EMT, MMT, FMT, SMM, fibrogenesis, angiogenesis, and impairment of immune surveillance in endometriosis; thus, endometriosis is not simply an inflammatory disease, and it should be redefined as a disease with a combined inflammatory and anti-inflammatory status.

However, there is a lack of large-scale studies using cytokine arrays to systematically analyze the dynamic changes in pro-inflammatory and anti-inflammatory cytokines during endometriosis disease progression. There
is a complex and interactive regulatory imbalance between pro-inflammatory cytokines/anti-inflammatory cytokines that is regulated by sex hormones, particularly estrogen, local metabolism, and the pro-inflammatory cytokines and anti-inflammatory cytokines themselves. This leads to the co-existence of high concentrations of pro-inflammatory and anti-inflammatory cytokines in endometriosis. Similar to tumors, anti-inflammatory factors may contribute to the new adaptive growth pattern of the ectopic endometrium by creating a tolerant endometriotic environment and have an important role in immune escape by ectopic lesions. Whether this process depends on inflammation regulation of the microenvironment of ectopic lesions by anti-inflammatory cytokines remains unclear. In addition, how the co-existence of pro-inflammatory and anti-inflammatory cytokines is generated and the regulatory mechanisms involved in endometriosis is not fully understood, which warrants further investigated.

Currently, the value of pro-inflammatory factors in the diagnosis of endometriosis is controversial [32, 33]. For diagnostic or evaluation purposes, reliable pro-inflammatory and anti-inflammatory cytokine arrays with high sensitivity and specificity must be identified. More realistic diagnostic tools will consist of a panel of biomarkers, including pro-inflammatory and anti-inflammatory cytokines, and other serum markers (e.g., CA-125), but the establishment of cytokine-based approaches for the management of endometriosis still represents a major challenge. These techniques, together with other non-invasive tools, such as ultrasound and magnetic resonance imaging (MRI), may markedly improve the diagnosis of endometriosis and the life quality of patients.

A single anti-inflammatory treatment (e.g., anti-TNF-α or anti-IFN-γ) is effective in mouse [29], rat [26, 27], baboon [23, 267] or human [24] models; however, they are less effective or ineffective [30, 31] in clinical trials, particularly in patients with severe and deep infiltrating endometriosis. As discussed earlier, many anti-endometriosis drugs or potential therapies, including hormonal drugs and immunoregulators, simultaneously affect the level and profile of cytokines in endometriosis. Therefore, compared with suppressing pro-inflammatory cytokines alone, targeting both pro-inflammatory and anti-inflammatory cytokines and/or enhancing immune surveillance by innate immune cells (macrophages and NK cells) may be more effective for the treatment of endometriosis. For therapeutic purposes, novel measures combining targeting of pro-inflammatory and anti-inflammatory factors present in the endometriotic lesion microenvironment, without inducing severe side effects, are required.

Furthermore, individualized therapies may be necessary for immune-associated interventions to treat endometriosis, and systematic immunization assessment is required before treatment. Therefore, the co-existence of pro-inflammatory and anti-inflammatory cytokines in endometriosis offers many possibilities for the establishment of novel diagnostics, models and therapeutic approaches, which requires further research.

Acknowledgements This work was supported by the National Natural Science Foundation of China (NSFC) (nos. 91542108, 81471513, 31671200, 81601354, 31600735 and 81571509), the Shanghai Rising-Star Program (no. 16QA1400800), the Innovation-oriented Science and Technology Grant from NPFPC Key Laboratory of Reproduction Regulation (CXX2017-2), the Program for Zhuxoue of Fudan University, the National Science Foundation of Jiangsu Province (no. BK20160128), the Fundamental Research Funds for the Central Universities (no. 021414380180), the Open Project Program of Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases (CN) (no. 14DZ2271700).

Author contributions MQL designed and wrote the review, and supervised and critically reviewed the complete manuscript. WJZ and HLY performed the literature search, drafted the manuscript and prepared the figures. JS, KKC and JM helped to perform revisions and critically discussed the completed manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be considered as potential conflicts of interest.

References


50. Tabibzadeh S, Becker JL, Parsons AK (2003) Endometriosis is associated with alterations in the relative abundance of proteins and IL-10 in the peritoneal fluid. Front Biosci 8:a70–a78
Anti-inflammatory cytokines in endometriosis


Anti-inflammatory cytokines in endometriosis


Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.